Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 31.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,054 shares of the company's stock after acquiring an additional 1,440 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Krystal Biotech were worth $948,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in KRYS. State Street Corp grew its holdings in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company's stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Krystal Biotech in the fourth quarter worth $15,989,000. Franklin Resources Inc. lifted its position in shares of Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after purchasing an additional 62,178 shares during the last quarter. Braidwell LP boosted its stake in shares of Krystal Biotech by 57.4% during the third quarter. Braidwell LP now owns 168,691 shares of the company's stock valued at $30,707,000 after purchasing an additional 61,512 shares during the period. Finally, TimesSquare Capital Management LLC grew its holdings in shares of Krystal Biotech by 39.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock worth $24,888,000 after purchasing an additional 44,646 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Krystal Biotech Trading Up 3.9 %

Shares of KRYS traded up $7.29 during midday trading on Monday, hitting $194.44. 261,855 shares of the company's stock traded hands, compared to its average volume of 284,099. The stock has a market capitalization of $5.60 billion, a price-to-earnings ratio of 65.03 and a beta of 0.87. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34. The firm's fifty day moving average is $166.67 and its 200-day moving average is $173.56.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same quarter last year, the company earned $0.30 earnings per share. The company's quarterly revenue was up 116.4% on a year-over-year basis. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on KRYS shares. HC Wainwright reiterated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Citigroup increased their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Krystal Biotech has an average rating of "Buy" and a consensus price target of $220.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).